Healthcare professionals warned not to use certain intravenous metronidazole, ondansetron, and ciprofloxacin due to potential contamination

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Healthcare professionals warned not to use certain intravenous metronidazole, ondansetron, and ciprofloxacin due to potential contamination

Published Date:

6/1/10

Series:

HAN ; 314

Language:

English

[PDF-611.60 KB]

Details:

Corporate Authors:

Centers for Disease Control and Prevention (U.S.) . United States. Food and Drug Administration. .

Keywords:

[+]

Description:

Tuesday, June 01, 2010, 10:25 EST (10:25 AM EST)

CDCHAN-00314-2010-06-01-ADV-N

The U.S. Food and Drug Administration (FDA) is alerting healthcare professionals not to use certain intravenous (IV) bags of metronidazole, ondansetron, and ciprofloxacin because of potential contamination. FDA has received reports of floating matter in IV bags manufactured by Claris Lifesciences Limited, in Ahmedabad, India. Microbiological analysis identified the matter in one of the bags as a Cladosporium mold. Molds of this type can cause infections in susceptible patients, such as immunocompromised individuals. At this time, FDA is not aware of any reports of injuries due to administration of these products. Affected products include any metronidazole, ondansetron, and ciprofloxacin manufactured by Claris Lifesciences Limited and sold under the following labels: Claris, Sagent Pharmaceuticals, Pfizer, West-Ward Pharmaceuticals

Document Type:

HAN Health Advisory

Collection(s):

Health Alert Network (HAN)

Place as Subject:

United States

Main Document Checksum:

[+]

Supporting Files:

No Additional Files

No Related Documents.

You May Also Like:

Epidemiologic Investigation of a Cluster of Neuroinvasive Bacillus cereus Infections in 5 Patients With Acute Myelogenous Leukemia

Personal Author:

Rhee, Chanu; Klompas, Michael; Tamburini, Fiona B.; Fremin, Brayon J.; Chea, Nora; Epstein, Lauren; Halpin, Alison Laufer; Guh, Alice; Gallen, Rachel; Coulliette, Angela; Gee, Jay; Hsieh, Candace; Desjardins, Christopher A.; Pedamullu, Chandra Sekhar; DeAngelo, Daniel J.; Manzo, Veronica E.; Folkerth, Rebecca Dunn; Milner, Danny A.; Pecora, Nicole; Osborne, Matthew; Chalifoux-Judge, Diane; Bhatt, Ami S.; Yokoe, Deborah S.;

Published:

Jul 01 2015

Source:

Open Forum Infect Dis. 2015; 2(3).

File Type:

[PDF - 245.76 KB]
Whole-Genome Sequencing to Determine Origin of Multinational Outbreak of Sarocladium kiliense Bloodstream Infections

Personal Author:

Etienne, Kizee A.; Roe, Chandler C.; Smith, Rachel M.; Vallabhaneni, Snigdha; Duarte, Carolina; Escandón, Patricia; Castañeda, Elizabeth; Gómez, Beatriz L.; de Bedout, Catalina; López, Luisa F.; Salas, Valentina; Hederra, Luz Maria; Fernández, Jorge; Pidal, Paola; Hormazabel, Juan Carlos; Otaíza-O’Ryan, Fernando; Vannberg, Fredrik O.; Gillece, John; Lemmer, Darrin; Driebe, Elizabeth M.; Engelthaler, David M.; Litvintseva, Anastasia P.;

Published:

Mar 2016

Source:

Emerg Infect Dis. 22(3):476-481.

Description:

We used whole-genome sequence typing (WGST) to investigate an outbreak of Sarocladium kiliense bloodstream infections (BSI) associated with receipt of contaminated antinausea medication among oncology patients in Colombia and Chile during 2013-2014. ...

File Type:

[PDF - 398.55 KB]
1989 Sexually transmitted diseases treatment guidelines

Corporate Author:

Center for Prevention Services (U.S.). Division of Sexually Transmitted Diseases.

Published:

September 1, 1989

Source:

MMWR. Morbidity and mortality weekly report. 1989; 38 Suppl 8:1-43.

Series:

MMWR. Morbidity and mortality weekly report ; v. 38, suppl. no. 8
DHHS publication ; no. (CDC) 85-8017

Description:

These guidelines for the treatment of patients with sexually transmitted diseases (STD) were established after consultation with a group of outside experts and staff of CDC. These guidelines are based on available efficacy data, practical applicabili...

File Type:

[PDF - 37.68 MB]
Medical care of ill disaster evacuees; additional diagnoses to consider

Corporate Author:

Centers for Disease Control and Prevention (U.S.)

Published:

June 9, 2006

Description:

Presenting symptoms -- Alphabetical listing of clinical summaries. : Common medical problems will continue to be the most prevalent conditions among evacuees. However, evacuees have been exposed to potentially contaminated flood waters and crowded li...

File Type:

[PDF - 205.21 KB]
Intravenous Artesunate for the Treatment of Severe and Complicated Malaria in the United States: Clinical Use under an Investigational New Drug Protocol

Personal Author:

Twomey, Patrick S.; Smith, Bryan L.; McDermott, Cathy; Marino, Anne; McCarthy, William; Kachur, S. Patrick; Ransom, Janet; Arguin, Paul M.;

Published:

Aug 25 2015

Source:

Ann Intern Med. 163(7):498-506.

Description:

Background : Quinidine gluconate, the only FDA-approved treatment for life-threatening malaria in the United States, has a problematic safety profile and is often unavailable in hospitals. : Objective : Assess the safety and clinical benefit of intra...

File Type:

[PDF - 397.77 KB]